Late-stage focus Leverage Annamycin's progression in late-stage development for AML and STS lung metastases to target partnering discussions with oncology CROs, pharma buyers, and academic collaborators seeking late-stage candidates with potential cardiotoxicity advantages.

Cardio-safety edge Highlight Annamycin's reduced cardiotoxicity as a differentiator in anthracycline therapies to engage hospitals and payers prioritizing safer regimens for relapsed/refractory AML and soft tissue sarcoma metastases.

Broad antiviral pipeline Position WP1122 and related antimetabolites as complementary platforms for antiviral indications (including COVID-19) to pursue industry partnerships, grant funding, and co-development deals with infectious disease franchises.

Immune modulation Frame WP1066 and WP1220 as immune/transcription modulators with tumor-targeting potential to attract collaboration with translational research groups and biotech investors focused on brain tumors, pancreatic cancer, and cutaneous lymphoma.

Strategic visibility Capitalize ongoing conference activity and abstracts at EHA and ASCO to generate scheduled partner meetings, increase library of potential collaborators, and accelerate out-licensing or co-development conversations with pharma players seeking novel oncology and virology assets.